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BACKGROUND: Cardiovascular disease (CVD) preven-
tion in diabetes requires broad-based treatment of
dyslipidemia, hypertension, and hyperglycemia. The
independent contribution of all combinations of risk
factor control to CVD risk has not been evaluated.
OBJECTIVE: To estimate the independent association
of control of glycosylated hemoglobin (A1C), systolic
blood pressure (SBP), and low-density lipoprotein cho-
lesterol (LDL-C) with risk of cardiovascular disease
hospitalization.
DESIGN: Non-concurrent longitudinal cohort study.
PATIENTS: The study included 26,636 patients with
type 2 diabetes who were members of an integrated
group model HMO with multiple A1C, SBP, and LDL-C
measurements.
MAIN MEASURES: Patients were followed for a mean
(SD) of 5.6 (2.5) years until they died or disenrolled, or
until 31 December 2010. The outcome was a first-
observed CVD hospitalization. Using the mean of all
A1C, SBP, and LDL-C measures during follow-up, we
created dichotomous categories of A1C control (< 7 %),
SBP control (< 130 mmHg), and LDL-C control
(< 100 mg/dL) to estimate the incidence rate of CVD
hospitalization associated with all combinations of risk
factor control adjusting for demographic and clinical
characteristics.
KEY RESULTS: Patients with no controlled risk factors
(18.2/1,000 person-years, 95 % CI 16.5−20.2) or with
only A1C in control (16.9, 15.0−19.0) had the highest
rate of CVD hospitalization, whereas those with all
three risk factors controlled (7.2, 6.2−8.4) or with SBP
and LDL-C in control (6.1, 5.1−7.2) had the lowest
rates. Those with only SBP or LDL-C in control, A1C
and SBP controlled, or A1C and LDL-C controlled had
statistically similar incidence between the highest and
lowest rates.
CONCLUSIONS: Maintaining SBP < 130 mmHg or LDL-
C < 100 mg/dL was significantly associated with
reduced CVD hospitalization risk, especially when both
risk factors were well controlled. Maintaining A1C < 7 %
was not independently associated with reduced CVD
hospitalization risk.
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INTRODUCTION
Management of type 2 diabetes requires a multifaceted
approach to optimize control of metabolic risk factors.1
Despite recent evidence that tight glycemic control does not
appear to reduce cardiovascular disease (CVD) risk,2–4
epidemiologic analyses have consistently shown an associ-
ation between higher glycosylated hemoglobin (A1C) and
poor CVD outcomes.5–7 In addition, evidence-based guide-
lines recommend more aggressive therapeutic targets for the
treatment of blood pressure and lipids in patients with
diabetes than are suggested for the general population.8,9
Evidence behind these recommendations comes from
clinical trials that studied treatment of specific risk factors
without simultaneously intervening on other risk factors.
One exception was the Steno-2 Study, which found that
intensive intervention with multiple drug combinations was
associated with significantly lower risk of CVD events,
although no attempt was made to ascertain the independent
contribution of each treated risk factor to CVD risk
reduction.10
Preventing CVD in diabetes requires broad-based treat-
ment of dyslipidemia, hypertension, and hyperglyce-
mia.11,12 Other observational studies have examined the
additive effects of glycemia and blood pressure and
glycemia and dyslipidemia.13,14 To our knowledge, howev-
er, no study has simultaneously evaluated the independent
contribution of all three of these risk factors to CVD risk.
Therefore, our objective was to study the CVD benefits of
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control of A1C, systolic blood pressure (SBP), and low-
density lipoprotein cholesterol (LDL-C), alone and in all
combinations, as predictors of CVD hospitalization in a
large cohort of patients with type 2 diabetes.
METHODS
Kaiser Permanente Northwest (KPNW) is an integrated
healthcare delivery system that provides comprehensive
medical services to approximately 480,000 individuals in a
75-mile radius around Portland, Oregon. An electronic
medical record has been in use since 1996 that links
encounter diagnoses, laboratory results, and pharmaceutical
dispensings. The present non-concurrent longitudinal cohort
study was approved by the KPNW Institutional Review
Board with a waiver of informed consent.
Sample Selection
Since 1989, KPNW has maintained a diabetes registry that
identifies members with diabetes from pharmacy, laboratory
and encounter databases. Patients enter the registry on the
basis of anti-hyperglycemic dispenses, diagnostic-level
fasting glucose or A1C values, and inpatient or outpatient
diagnoses (ICD-9-CM 250.xx). Clinicians remove patients
from the registry who they believe have been entered
erroneously. We identified all patients who entered the
registry in 2007 or earlier and who had an eligibility period
between 2002 and 2010 (n=53,250). To ensure we were
studying patients with type 2 diabetes, we excluded 5,514
individuals with an insulin dispense within the first year of
diabetes recognition. Patients under age 18 years (n=378)
were also excluded. All patients were required to have A1C,
LDL-C, and SBP measured after diabetes diagnosis but no
more than 6 months apart, resulting in the exclusion of
12,681 patients. The first occurrence of the three-test
combination was used as the baseline set of measurements,
and the latest date that one of the baseline measurements was
recorded was defined as the index date. We excluded 4,042
individuals who had a CVD hospitalization prior to the index
date. Last, all subjects were required to have at least one
additional A1C, SBP and LDL-C measurement during
follow-up, resulting in a final sample size of 26,636 patients.
Outcome, Observation Period, and Exposure
Variables
Using the electronic medical record, we followed patients
from the index date until a hospital admission was recorded
with a primary diagnosis of coronary heart disease (ICD-9-
CM codes 410.x, 411.x, 413.x, 414.x) or stroke (430.x,
431.x, 432.x, 434.x, 435.x, 436.x, 437.1), defining the
composite as CVD. Patients were followed from index date
until they first experienced the outcome, died or left the
health plan, or until 31 December 2010.
We used the mean of all available measures of A1C, SBP,
and LDL-C during the observation period to examine the
association between these risk factors and CVD hospital-
izations. We analyzed each risk factor continuously and
as dichotomous variables, using guideline-recommended
levels of control (A1C < 7 %, SBP < 130 mmHg, LDL-C
< 100 mg/dL). In addition, we created eight categories
representing all possible combinations of risk factor control:
1) none of the three risk factors controlled; 2) only A1C
controlled; 3) only SBP controlled; 4) only LDL-C
controlled; 5) A1C and SBP controlled, but not LDL-C;
6) A1C and LDL-C controlled, but not SBP; 7) SBP and
LDL-C controlled, but not A1C; and 8) A1C, SBP, and
LDL-C all controlled.
Covariates
Covariates included baseline age sex, race, and duration of
diabetes (defined as the time between entry into the diabetes
registry and the index date). Although we excluded patients
with a previous CVD hospitalization, some patients had
CVD diagnosed in the outpatient setting during observation.
Therefore, we included a covariate for outpatient-diagnosed
CVD (same ICD-9 codes as for the outcome), as well as the
following comorbidities: heart failure (ICD-9 428.x),
retinopathy (250.5, 369.x, 362.01-362.07), neuropathy
(250.6, 358.1, 713.5, 337.1, 357.2), depression (296.2,
296.3, 400.4, 309.1, 311), and chronic kidney disease (GFR
<60 mL/min/1.73 m2, estimated from serum creatinine
using the Modification of Diet in Renal Disease (MDRD)
equation15). We also controlled for use of specific anti-
hyperglycemic agents (metformin, sulphonylureas, thiazoli-
dinediones, insulin, other agents), antihypertensive agents
(angiotensin-converting enzyme [ACE] inhibitors or angio-
tensin receptor blockers [ARBs], β-blockers, other agents),
antilipidemic agents (statins, fibrates, other agents), and
antidepressants used within 100 days of the event (or the
end of observation).
Statistical Analyses
We compared demographic and clinical characteristics,
comorbidities, and pharmacotherapies among patients who
did and did not experience a CVD event using t-tests for
continuous variables and χ2 tests for categorical variables.
P values<0.05 were considered significant. We also
compared A1C, SBP, and LDL-C among patients who did
and did not experience a CVD event using t-tests for the
continuous values and χ2 tests for the dichotomous
indicators of risk factor control and for the distribution of
all possible combinations of risk factor control.
692 Nichols et al.: Risk Factor Control and CVD Risk JGIM
We calculated incidence rates for CVD hospitalizations
per 1,000 person-years for each of the possible combina-
tions of risk factor control adjusted for age, sex and diabetes
duration, using generalized linear regression with Poisson
errors and the natural log of person-years as an adjustment
for unequal follow-up using Proc Genmod in SAS v9.2
(SAS Institute, Cary, NC). A p value of 0.05 was used to
calculate 95 % confidence intervals. We used Cox propor-
tional hazards regression analysis to further adjust for
clinical characteristics, comorbidities, and pharmacotherapy
variables described above. The first Cox model used
continuous measures of A1C, SBP, and LDL-C, a second
used non-mutually exclusive dichotomous variables of risk
factor control, and the final regression model included all
possible combinations of risk factor control, using “All
Three Risk Factors in Control” as the reference group. We
tested the proportional hazards assumption by including
time-dependent variables for all combinations of risk factor
control in a Cox model; none were significant at p<0.05,
satisfying the assumption.
Sensitivity Analyses
We conducted three sensitivity analyses to confirm our
findings. First, we used baseline measures of A1C, SBP,
and LDL-C to analyze their association with risk of CVD
hospitalization. Second, we substituted the last A1C, SBP,
or LDL-C measurement prior to the event (or end of follow-
up) for mean values and re-estimated the Cox models.
Third, we repeated our analysis using mean values
excluding individuals with mean A1C values < 6 %.
RESULTS
Of the 26,636 study patients, 1,943 (7.3 %) experienced a
CVD hospitalization during the observation period (Table 1).
Patients who experienced the outcome were older, more
likely to be men, and had longer diabetes duration compared
with those who remained event-free. All comorbidities
except depression were more common among patients who
experienced a CVD hospitalization as were use of several
medications.
Mean A1C during follow-up did not differ between those
who did and did not experience a CVD hospitalization
(Table 2). However, mean SBP and LDL-C were signifi-
cantly greater among those who experienced an event.
Similarly, the proportion of patients with A1C in control
was not significantly different, but the proportion with SBP
control and LDL-C control was significantly lower among
those who experienced an event.
Figure 1 displays CVD hospitalization incidence rates per
1,000 person-years for each of the eight mutually exclusive
categories of A1C, SBP, and LDL-C control, adjusted for
age, sex, and duration of diabetes. Patients with no controlled
risk factors or with only A1C controlled had the highest
CVD hospitalization rates, whereas those with all three risk
factors controlled or with SBP and LDL-C controlled had the
lowest rates. Patients with only SBP controlled, only LDL-C
controlled, A1C and SBP controlled, or A1C and LDL-C
controlled had statistically similar incidence rates that were
significantly lower than those with no risk factors or only
A1C controlled, and significantly higher than those with SBP
and LDL-C or all three risk factors controlled.
After adjustment for demographic and clinical character-
istics, comorbidities and pharmacotherapies, an increase of






n (%) 24,693 (92.7) 1,943 (7.3) –
Baseline age, years 58.6 (12.0) 65.5 (11.1) < 0.001
Men 49.7 56.4 < 0.001
African-American 3.2 2.9 0.475
Smoker 13.1 13.6 0.558
Duration of diabetes
(at baseline), years
3.4 (4.2) 5.2 (5.1) < 0.001
Baseline BMI
(kg/m2)
33.7 (7.9) 32.0 (6.7) < 0.001
Baseline eGFR
(ml/min/1.73 m2)
92 (30) 81 (28) < 0.001
Baseline HDL-C
(mg/dL)
48 (11) 47 (11) 0.010
Baseline triglycerides
(mg/dL)
224 (218) 227 (190) 0.567
Total years
of follow-up
5.5 (2.5) 6.4 (2.2) < 0.001
Years to event n/a 3.9 (2.2) –
Comorbidities*
Cardiovascular disease 28.0 67.1 < 0.001
Cerebrovascular disease 10.2 23.3 < 0.001
Heart failure 13.4 25.9 < 0.001
Chronic kidney disease 21.0 34.6 < 0.001
Neuropathy 35.0 43.8 < 0.001
Retinopathy 24.7 34.3 < 0.001




58.0 63.4 < 0.001
Beta-blockers 29.7 53.1 < 0.001
Other
antihypertensives
40.7 53.2 < 0.001
Metformin 42.7 37.5 < 0.001
Sulfonylureas 31.3 37.6 < 0.001




Insulin 22.0 27.0 < 0.001
Statins 55.4 59.0 0.002




Antidepressants 24.6 25.5 0.348
Data are mean (standard deviation) or percent
*Comorbidities assessed from diagnoses occurring anytime prior to
CVD hospitalization or end of observation if no hospitalization
†Pharmacotherapy based on receipt of a dispense within 100 days
prior to CVD hospitalization or last 100 days of observation if no
hospitalization
ACE angiotensin-converting enzyme; ARB angiotensin receptor
blocker; BMI body mass index; CVD cardiovascular disease; eGFR
estimated glomerular filtration rate; HDL-C high-density lipoprotein
cholesterol; TZD thiazolidinediones
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one standard deviation of SBP was associated with a 40 %
increased risk of CVD hospitalization, as was one standard
deviation increase of LDL-C (Table 3). Mean A1C was not
associated with CVD risk. When A1C control, SBP control,
and LDL-C control were included in models as non-
mutually exclusive variables, SBP and LDL-C control were
protective while A1C control was associated with a 14 %
increased risk of CVD hospitalization. In adjusted models
using all possible combinations of risk factor control, all
categories, except having both SBP and LDL-C controlled,
produced statistically significant adjusted hazard ratios
relative to those with all three risk factors controlled.
Results of the sensitivity analyses are shown in the online
appendix, supplementary Table 1. Associations between
baseline measures of A1C, SBP, and LDL-C and CVD
hospitalization were substantially weaker than mean
values during observation. Substituting last values ob-
served during follow-up produced results similar to those
obtained using mean values. Exclusion of patients with
mean A1C < 6 % attenuated the risk associated with A1C
control, but did not change the results. Supplementary
Table 2 in the online appendix shows the mean risk factor
levels for the eight mutually exclusive categories. Similar
values were seen among categories that indicated a
specific risk factor was controlled and also among
categories that indicated a specific risk factor was not
controlled.
Table 2. Unadjusted Mean A1C, Systolic Blood Pressure, and
LDL-C Over Entire Observation Period, Proportion of Patients
with A1C in Control, Systolic Blood Pressure in Control, LDL-C










Mean (SD) A1C (%) 7.3 % (1.2) 7.3 % (1.2) 0.581
Mean (SD) SBP
(mm Hg)
132 (11) 137 (13) < 0.001
Mean (SD)
LDL-C (mg/dL)
97 (26) 102 (29) < 0.001
Non−Mutually Exclusive Categories
% A1C in control
(< 7 %)
45.6 47.2 0.174
% SBP in control
(< 130 mmHg)
44.1 27.9 < 0.001
% LDL-C in control
(< 100 mg/dL)
59.5 51.9 < 0.001
Mutually Exclusive Categories















% All three in control 13.8 9.2
Data are mean (standard deviation) or percent
A1C hemoglobin A1c; CVD cardiovascular disease; LDL-C low-


















































Incidence Rates of First Cardiovascular Disease Hospitalization   
Figure 1. Incident rate per 1,000 person-years of first cardiovascular disease hospitalization, adjusted for age, sex, and duration of diabetes. The
error bars represent 95% confidence intervals for the incidence rates.A1C hemoglobin A1c; LDL LDL cholesterol; SBP systolic blood pressure.
694 Nichols et al.: Risk Factor Control and CVD Risk JGIM
DISCUSSION
Clinical management of type 2 diabetes includes control of
glycemia, blood pressure, and LDL-C to reduce the risk of
CVD and other complications.1 In the current observational
study of 26,636 patients with type 2 diabetes followed over
a mean of approximately 6 years, we found that controlling
all three risk factors was associated with an incidence rate
of CVD hospitalization that was approximately 2.5 times
lower than if none of the risk factors was below guideline-
recommended levels.
Despite guidelines recommending multi-factorial treat-
ment of cardiometabolic risk factors, there are surprisingly
few studies that have examined the simultaneous benefits of
risk factor control. The ADVANCE study reported that
combined treatment of A1C and SBP (compared with no
active intervention) had no effect on the incidence of
macrovascular events, but lipid control was not included.16
A large observational study found that tight control of A1C
and SBP reduced CVD risk by 33 %, but did not attempt to
disentangle the relative benefits of the two risk factors, nor
did it include lipid control as an analysis variable.17 The
UKPDS explored the additive effects of glycemia and blood
pressure,13 and a report from the Swedish National Diabetes
Register analyzed the additive effects of glycemia and
dyslipidemia.14 To our knowledge, the only study to
evaluate all three cardiometabolic risk factors simultaneous-
ly was the Steno-2 study, which demonstrated that intensive
treatment of A1C, SBP, and lipids reduced the risk of
cardiovascular events by 53 %10; an effect that was
sustained well after the intervention ceased.18 The Steno-2
sample size (n=160) was too small to determine which risk
factor or combination of risk factors accounted for the
effect. To our knowledge, the current study is the first to
simultaneously evaluate the contribution of all possible
combinations of A1C, SBP, and LDL-C control to CVD
risk reduction.
Maintaining A1C control below 7 % was not associated
with reduced CVD hospitalization risk below that obtained
with SBP and LDL-C control. CVD hospitalization incidence
per 1,000 person-years among those with A1C in control but
neither of the other risk factors in control was statistically
similar to incidence found among those with no risk factors
in control; incidence among those with A1C in control in
addition to either SBP or LDL-C was statistically similar to
the rate among those with only SBP or LDL-C in control,
respectively; and control of both SBP and LDL-C, but not
A1C, produced a statistically similar rate to that of patients
who had all three risk factors controlled. Our findings will
likely contribute to the emerging controversy over optimal
A1C levels. Glycemic control remains a cornerstone of good
diabetes care. Despite clinical trials that found no CVD
benefit and possible harm with tight control,2–4 an A1C level
< 7 % is still considered optimal for most patients,12 although
a less stringent patient-centered approach has recently been
recommended.19 The recommendation to achieve A1C < 7 %
was initially due to UKPDS evidence that intensive control
substantially reduced microvascular complications,20 and
more recent clinical trials re-affirm the microvascular benefit
of low A1C levels.3,21 The nature of the relationship between
A1C and CVD risk, however, remains unclear. Over a
decade ago, the UKPDS found that each 1 % reduction in
A1C was associated with a 14 % reduced risk of myocardial
infarction, with no threshold below which risk reduction
could not be obtained.5 More recent observational studies
conducted on large samples in Sweden and New Zealand
reported similar findings.22,23 However, two other studies
found a U-shaped relationship, with levels of A1C
< 6%−6.5 % and > 8.5 % conferring risk of cardiovascular
outcomes or death.6,24 A post-hoc analysis from the
ADVANCE trial found evidence of a threshold such that
A1C < 7 % did not reduce macrovascular events.25 The
current study did not find an association between mean A1C
< 7 % and reduced CVD risk after controlling for other risk
factors. One possible explanation is that 90 % of patients had
mean A1C levels < 9 %; the benefits of additional glycemic
control in a relatively well-controlled sample may be difficult
to detect. Our A1C results may also be confounded by non-
random use of anti-hyperglycemic agents, specifically met-
formin and sulfonylureas, that are known to have differential
CVD effects.26,27
All categories of risk factor control that included SBP
were associated with lower CVD hospitalization incidence
Table 3. Adjusted Hazard Ratios for Continuous Measures of
Risk Factors, Dichotomous Measures of Risk Factor Control, and
All Possible Combinations of Risk Factor Control
Adjusted Hazard
Ratios* (95 % CI)
p value
Continuous Measures
A1C (per SD) 1.01 (0.95−1.08) 0.661
SBP (per SD) 1.40 (1.33−1.47) < 0.001
LDL-C (per SD) 1.40 (1.33−1.47) < 0.001
Non-Mutually Exclusive Categories
A1C in control (< 7 %) 1.14 (1.02−1.27) 0.024
SBP in control (< 130 mmHg) 0.63 (0.56−0.71) < 0.001
LDL-C in control (< 100 mg/dL) 0.52 (0.47−0.57) < 0.001
Mutually Exclusive Categories
None in control 2.75 (2.25−3.37) < 0.001
Only A1C in control 2.76 (2.25−3.40) < 0.001
Only SBP in control 1.76 (1.36−2.26) < 0.001
Only LDL-C in control 1.31 (1.07−1.62) 0.011
A1C/SBP in control 1.90 (1.46−2.48) < 0.001
A1C/LDL-C in control 1.63 (1.33−1.99) < 0.001
SBP/LDL-C in control 0.78 (0.60−1.00) 0.054
All three in control ref –
A1C hemoglobin A1c; CI confidence interval; CVD cardiovascular
disease; LDL-C low-density lipoprotein cholesterol; SBP systolic
blood pressure
*Adjusted for age, sex, race, diabetes duration, body mass index, HDL
cholesterol, triglycerides, smoking, and presence of cardiovascular
disease, heart failure, retinopathy, neuropathy, depression, chronic
kidney disease, and use of metformin, sulphonylureas, thiazolidine-
diones, insulin, ACE inhibitors or angiotensin receptor blockers, β-
blockers, other anti-hypertensive agents, statins, fibrates, and anti-
depressants
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than similar categories that did not. For example, CVD
hospitalization incidence among those with only SBP in
control was lower than among those with no risk factors in
control, and incidence among those with SBP and LDL-C
in control was lower than among those with only LDL-C in
control. Our definition of SBP control (< 130 mmHg) was
based on the American Diabetes Association guidelines that
were in place during the observation period.1 However, this
level of SBP control is somewhat controversial. The
American College of Cardiology/American Heart Associa-
tion, for example, holds that < 140 mmHg is sufficient,28 a
level supported by recent trials. The ACCORD trial found
that targeting SBP < 120 mmHg, as compared with
< 140 mmHg, did not reduce the rate of major cardiovas-
cular events.29 Another recent study also suggested that
tight SBP control (< 130 mmHg) was not associated with
improved CVD outcomes relative to usual control of 130−139
mmHg, but did provide substantial benefit compared with
SBP ≥ 140 mmHg.30 The Ongoing Telmisartan Alone and in
combination with Ramipril Global Endpoint Trial (ONTAR-
GET) found no benefit in fatal or nonfatal cardiovascular
outcomes by reducing SBP below 130 mmHg.31 Neverthe-
less, our results suggest that achieving and maintaining SBP at
that level is associated with CVD risk reduction.
Similar to SBP control, we found that all categories of
risk factor control that included LDL-C were associated
with lower CVD hospitalization incidence than similar
categories that did not. CVD hospitalization incidence
among those with only LDL-C in control was lower than
among those with no risk factors in control, and CVD
hospitalization incidence among those with SBP and LDL-
C in control was lower than among those with only SBP in
control. Because diabetes may be a cardiovascular risk
equivalent,32 current guidelines recommend an LDL-C
target of < 100 mg/dL,8 or perhaps as low as < 70 mg/dL,
for patients with diabetes.33 We did not test categories of
control other than < 100 mg/dL, so we cannot determine
whether a “floor” for LDL-C control exists.
Strengths of the study include its large sample size and
the designed intent to study all possible combinations of
control of three key cardiometabolic risk factors. There are
several limitations. We required all three risk factors to be
measured within 6 months of each other, resulting in the
exclusion of 27 % of the eligible sample. However,
excluded patients did not differ demographically from the
study sample. As an observational study, we cannot
conclude that the reported associations between risk factor
control and CVD hospitalization risk are causal. Although
we controlled for characteristics and risk factors that might
affect CVD, residual confounding may exist. We included
covariates for medications and duration of diabetes, but did
not explore the myriad interactions between specific
medications, dosages, and duration of therapy. We used
death as a censoring event and some deaths could have
occurred from cardiovascular causes outside the hospital,
resulting in an underestimate of CVD rates. Moreover, A1C
control may affect mortality differently than CVD hospital-
izations.2,24 We did not attempt to adjudicate CVD
hospitalizations, relying on the accuracy of coding of
inpatient diagnoses.
In summary, we found that maintaining SBP < 130 mmHg
or LDL-C < 100 mg/dL over a mean follow-up of
approximately 6 years was significantly associated with
reduced risk of CVD hospitalization. The effect was
especially strong when both of these risk factors were well
controlled. Maintaining A1C < 7 % in an already
well-controlled population was not associated with CVD
hospitalization risk reduction.
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